The biotin-RNA pull-down assay and reporter assay data showed that NK-Exos-loaded miR-3607-3p could target the IL-26 expressed in the pancreatic TME, inhibiting growth and the development of pancreatic tumor cells in vitro and in vivo. Here, IL26 is linked to pancreatic neoplasm.